Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:SNDXNASDAQ:TKNONASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$29.83+0.8%$28.57$23.23▼$42.29$951.10M0.63410,598 shs669,952 shsSNDXSyndax Pharmaceuticals$9.48-2.2%$11.10$8.58▼$25.07$833.80M0.741.81 million shs2.64 million shsTKNOAlpha Teknova$5.56+0.9%$6.10$1.16▼$10.37$294.46M0.4408,624 shs200,340 shsWVEWAVE Life Sciences$6.57-4.8%$6.62$4.25▼$16.74$1.06B-1.041.33 million shs1.21 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+0.78%+2.23%+1.22%-0.73%-7.22%SNDXSyndax Pharmaceuticals-2.17%-7.51%-10.99%-30.85%-50.26%TKNOAlpha Teknova+0.91%+1.46%-14.46%-5.12%+247.50%WVEWAVE Life Sciences-4.78%-5.47%+8.77%-31.49%+15.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical3.8389 of 5 stars3.41.00.03.02.40.81.9SNDXSyndax Pharmaceuticals3.0648 of 5 stars3.50.00.04.42.60.00.0TKNOAlpha Teknova2.8235 of 5 stars3.53.00.00.03.80.80.6WVEWAVE Life Sciences4.1528 of 5 stars3.51.00.04.81.44.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7546.66% UpsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$35.91278.79% UpsideTKNOAlpha Teknova 3.00Buy$8.5052.88% UpsideWVEWAVE Life Sciences 2.92Moderate Buy$20.50212.02% UpsideCurrent Analyst Ratings BreakdownLatest TKNO, SNDX, WVE, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025WVEWAVE Life SciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/29/2025WVEWAVE Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/8/2025WVEWAVE Life SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$18.003/26/2025WVEWAVE Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/24/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.52$12.43 per share2.40$7.10 per share4.20SNDXSyndax Pharmaceuticals$23.68M34.45N/AN/A$3.38 per share2.80TKNOAlpha Teknova$37.74M7.87N/AN/A$1.55 per share3.59WVEWAVE Life Sciences$108.30M9.35N/AN/A$1.37 per share4.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.2224.454.96N/A6.61%99.08%15.14%8/6/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)TKNOAlpha Teknova-$26.75M-$0.48N/AN/AN/A-60.90%-28.48%-19.73%8/12/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%8/6/2025 (Estimated)Latest TKNO, SNDX, WVE, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/8/2025Q1 2025TKNOAlpha Teknova-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million5/8/2025Q1 2025WVEWAVE Life Sciences-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.301.081.01SNDXSyndax Pharmaceuticals1.535.805.75TKNOAlpha Teknova0.175.644.71WVEWAVE Life SciencesN/A2.952.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ASNDXSyndax PharmaceuticalsN/ATKNOAlpha Teknova13.81%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%SNDXSyndax Pharmaceuticals4.10%TKNOAlpha Teknova12.50%WVEWAVE Life Sciences29.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million82.52 millionOptionableTKNOAlpha Teknova24053.44 million46.76 millionNot OptionableWVEWAVE Life Sciences240154.13 million109.28 millionOptionableTKNO, SNDX, WVE, and COLL HeadlinesRecent News About These CompaniesWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...June 20 at 8:12 PM | finance.yahoo.comWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific SessionsJune 20 at 4:01 PM | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?June 20 at 12:55 PM | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?June 19 at 4:48 AM | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in StockJune 14, 2025 | insidertrades.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives $21.17 Average Target Price from AnalystsJune 14, 2025 | americanbankingnews.comWave Life Sciences Ltd. (NASDAQ:WVE) Director Gregory L. Verdine Sells 30,000 SharesJune 13, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Coverage Initiated by Analysts at Raymond JamesJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Comments on WVE FY2026 EarningsJune 12, 2025 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Now Covered by Raymond JamesJune 11, 2025 | marketbeat.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from AnalystsJune 11, 2025 | marketbeat.comBrokers Offer Predictions for WVE FY2026 EarningsJune 10, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's WhyJune 9, 2025 | marketbeat.comTwo Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)June 3, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)June 2, 2025 | marketbeat.comNuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 31, 2025 | marketbeat.comWave Life Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Two Sigma Investments LPMay 29, 2025 | marketbeat.comBank of America Corp DE Acquires 160,820 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)May 29, 2025 | marketbeat.comWave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical OfficerMay 28, 2025 | globenewswire.comPolar Asset Management Partners Inc. Has $6.89 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTKNO, SNDX, WVE, and COLL Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$29.83 +0.23 (+0.78%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$29.81 -0.02 (-0.07%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$9.48 -0.21 (-2.17%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.48 -0.01 (-0.05%) As of 06/20/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Alpha Teknova NASDAQ:TKNO$5.56 +0.05 (+0.91%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.56 +0.01 (+0.09%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.WAVE Life Sciences NASDAQ:WVE$6.57 -0.33 (-4.78%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.51 -0.06 (-0.85%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
